[1] 黄健.中国泌尿外科和男科疾病诊断治疗指南(2019版)[M].北京:科学出版社, 2019:27-78.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al.Cancer statistics, 2022[J].CA Cancer J Clin, 2022, 72(1):7-33.
[3] 郑曦, 张青, 郭宏骞.热灌注化疗治疗非肌层浸润性膀胱癌的研究进展[J].东南大学学报(医学版), 2016, 35(4):617-621.
[4] WALTHER R, ZELIKIN A N.Chemical(neo)glycosylation of biological drugs[J].Adv Drug Deliv Rev, 2021, 4(171):62-76.
[5] VARKI A.Biological roles of glycans[J].Glycobiology, 2017, 27(1):3-49.
[6] MUNKLEY J, ELLIOTT D J.Hallmarks of glycosylation in cancer[J].Oncotarget, 2016, 7(23):35478-35489.
[7] VAN TOL W, WESSELS H, LEFEBER D J.O-glycosylation disorders pave the road for understanding the complex human O-glycosylation machinery[J].Curr Opin Struct Biol, 2019, 56:107-118.
[8] SCHJOLDAGER K, NARIMATSU Y, JOSHI H, et al.Global view of human protein glycosylation pathways and functions[J].Nat Rev Mol Cell Biol, 2020, 21(12):729-749.
[9] DINIZ F, COELHO P, DUARTE H, et al.Glycans as Targets for Drug Delivery in Cancer[J].Cancers(Basel), 2022, 14(4):1-19.
[10] CLERC F, REIDING K, JANSEN B, et al.Human plasma protein N-glycosylation[J].Glycoconj J, 2016, 33(3):309-343.
[11] PINHO S S, REIS C A.Glycosylation in cancer:mechanisms and clinical implications[J].Nat Rev Cancer, 2015, 15(9):540-555.
[12] BAGDONAITE I, PALLESEN E, YE Z, et al.O-glycan initiation directs distinct biological pathways and controls epithelial differentiation[J].EMBO Rep, 2020, 21(6):1-17.
[13] KLAVER E, ZHAO P, MAY M, et al.Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing[J].Dis Model Mech, 2019, 12(6):1-11.
[14] TAJADURA-ORTEGA V, GAMBARDELLA G, SKINNER A, et al.O-linked mucin-type glycosylation regulates the transcriptional programme downstream of EGFR[J].Glycobiology, 2021, 31(3):200-210.
[15] CHRISTIANSEN M N, CHIK J, LEE L, et al.Cell surface protein glycosylation in cancer[J].Proteomics, 2014, 14(4-5):525-546.
[16] ZHU L, XU Y, WEI X, et al.Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-Specific Glycosylation[J].Angew Chem Int Ed Engl, 2021, 60(33):18111-18115.
[17] DHANISHA S S, GURUVAYOORAPPAN C, DRISHYA S, et al.Mucins:Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets[J].Crit Rev Oncol Hematol, 2018, 122:98-122.
[18] 宋孟迪, 曾洁, 贾甜, 等.微生物来源的唾液酸转移酶研究进展[J].食品工业科技, 2019, 40(05):305-310.
[19] LI T, ZHANG H, GUO Y, et al.Efficient chemoenzymatic synthesis of fluorinated sialyl Thomsen-Friedenreich antigens and investigation of their characteristics[J].Eur J Med Chem, 2020, 208:112776.
[20] 刘丽娜, 陈茜茜, 汪淑晶.糖基化在肿瘤相关上皮间质转化中的作用[J].中国肿瘤生物治疗杂志, 2018, 25(12):1316-1321.
[21] KUDELKA M R, JU T, HEIMBURG-MOLINARO J, et al.Simple sugars to complex disease——mucin-type O-glycans in cancer[J].Adv Cancer Res, 2015, 126:53-135.
[22] JIAN Y, XU Z, XU C, et al.The Roles of Glycans in Bladder Cancer[J].Front Oncol, 2020, 10:957-968.
[23] EBLE J A, NILAND S.The extracellular matrix in tumor progression and metastasis[J].Clin Exp Metastasis, 2019, 36(3):171-198.
[24] LIU Y C, YEN H Y, CHEN C Y, et al.Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells[J].Proc Natl Acad Sci U S A, 2011, 108(28):11332-11337.
[25] YONEVAMA M S, TOBISAWA Y, HATAKEYAMA S, et al.A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I in bladder cancer[J].European Urology Supplements, 2018, 17(2):e1341-e1342.
[26] SUZUKI Y, SUTOH M, HATAKEYAMA S, et al.MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis[J].Int J Oncol, 2012, 40(6):1831-1838.
[27] TSUBOI S, SUTOH M, HATAKEYAMA S, et al.A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans[J].EMBO J, 2011, 30(15):3173-3185.
[28] SUN Z, XUE H, WEI Y, et al.Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis[J].Clin Sci(Lond), 2019, 133(10):1167-1184.
[29] JIA L, LI J, LI P, et al.Site-specific glycoproteomic analysis revealing increased core-fucosylation on FOLR1 enhances folate uptake capacity of HCC cells to promote EMT[J].Theranostics, 2021, 11(14):6905-6921.
[30] RADHAKRISHNAN P, DABELSTEEN S, MADSEN F B, et al.Immature truncated O-glycophenotype of cancer directly induces oncogenic features[J].Proc Natl Acad Sci U S A, 2014, 111(39):E4066-4075.
[31] FU C, ZHAO H, WANG Y, et al.Tumor-associated antigens:Tn antigen, sTn antigen, and T antigen[J].HLA, 2016, 88(6):275-286.
[32] MIN X, WEN J, ZHAO L, et al.Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma[J].Mol Oncol, 2018, 12(9):1480-1497.
[33] MUNKLEY J.The Role of Sialyl-Tn in Cancer[J].Int J Mol Sci, 2016, 17(3):275-284.
[34] LU Y C, CHEN C N, CHU C Y, et al.Calreticulin activates beta1 integrin via fucosylation by fucosyltransferase 1 in J82 human bladder cancer cells[J].Biochem J, 2014, 460(1):69-78.
[35] AZIZ F, KHAN I, SHUKLA S, et al.Partners in crime:The Lewis Y antigen and fucosyltransferase IV in Helicobacter pylori-induced gastric cancer[J].Pharmacol Ther, 2022, 232:107994.
[36] ZHANG Y, ZHANG D, LV J, et al.MiR-125a-5p suppresses bladder cancer progression through targeting FUT4[J].Biomed Pharmacother, 2018, 108:1039-1047.
[37] SHAN M, YANG D, DOU H, et al.Fucosylation in cancer biology and its clinical applications[J].Prog Mol Biol Transl Sci, 2019, 162:93-119.
[38] YANG G, TAN Z, LU W, et al.Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy[J].J Proteome Res, 2015, 14(2):639-653.
[39] GUO J, LI X, TAN Z, et al.Alteration of N-glycans and expression of their related glycogenes in the epithelial-mesenchymal transition of HCV29 bladder epithelial cells[J].Molecules, 2014, 19(12):20073-20090.
[40] XU Q, NIU X, WANG W, et al.Specific N-glycan alterations are coupled in EMT induced by different density cultivation of MCF 10A epithelial cells[J].Glycoconj J, 2017, 34(2):219-227.
[41] JIE X, FONG W P, ZHOU R, et al.USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-beta2 transcription[J].Cell Death Differ, 2021, 28(7):2095-2111.
[42] NIEDWOROK C, ROCK K, KRETSCHMER I, et al.Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer[J].PLoS One, 2013, 8(11):e80084.
[43] APPUNNI S, ANAND V, KHANDELWAL M, et al.Small Leucine Rich Proteoglycans(decorin, biglycan and lumican) in cancer[J].Clinica Chimica Acta, 2019, 491:1-7.
[44] SAINIO A, NYMAN M, LUND R, et al.Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies[J].PLoS One, 2013, 8(10):e76190.
[45] BAGHY K, RESZEGI A, TÁTRAI P, et al.Decorin in the Tumor Microenvironment[J].Adv Exp Med Biol, 2020, 1272:17-38.
[46] FERRO M, GIUBERTI G, ZAPPAVIGNA S, et al.Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms[J].Oncol Rep, 2012, 27(2):409-415.
[47] HAKOMORI S I.Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility[J].FEBS Lett, 2010, 584(9):1901-1906.
[48] LEE J, HWANG H, KIM S, et al.Comprehensive Profiling of Surface Gangliosides Extracted from Various Cell Lines by LC-MS/MS[J].Cells, 2019, 8(11):1-14.
[49] MITSUZUKA K, HANDA K, SATOH M, et al.A specific microdomain("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9[J].J Biol Chem, 2005, 280(42):35545-35553.
[50] DAL MORO F, VALOTTO C, GUTTILLA A, et al.Urinary markers in the everyday diagnosis of bladder cancer[J].Urologia, 2013, 80(4):265-275.
[51] BAMATO M.Theory of bladder urothelial carcinoma by serum tumor markers CA19-9 and bHCG[J].Cancer Research and Cellular Therapeutics, 2017, 1(1):1-3.
[52] JHA D K, MITTAL A, GUPTA S P, et al.Significance of CA19-9 in predicting the prognosis of urothelial carcinoma:a hospital based study from Nepal[J].Asian Pac J Cancer Prev, 2013, 14(7):4067-4069.
[53] TRINCHERA M, ARONICA A, DALL'OLIO F.Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers[J].Biology(Basel), 2017, 6(1):1-18.
[54] LIMA L, NEVES M, OLIVEIRA M I, et al.Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases[J].Urologic Oncology:Seminars and Original Investigations, 2017, 35(12):675.e1-e8.
[55] LOUREIRO L R, SOUSA D P, FERREIRA D, et al.Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids[J].Sci Rep, 2018, 8(1):12196-12214.
[56] ZEIDAN Q, HART G W.The intersections between O-GlcNAcylation and phosphorylation:implications for multiple signaling pathways[J].J Cell Sci, 2010, 123(1):13-22.
[57] YANG W H, NAM H W, KIM D H, et al.NFκB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions[J].Proc Natl Acad Sci USA, 2008, 105(45):17345-17350.
[58] BAPU D, RUNIONS J, KADHIM M, et al.N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells:a role for truncated O-glycans in metastatic mechanisms[J].Cancer Lett, 2016, 375(2):367-374.
[59] RÓZANSKI W, MARKOWSKI M, BLEWNIEWSKI M, et al.C79 Mgea5 and Ogt as biomarkers for the detection of bladder malignancies in urine[J].European Urology Supplements, 2011, 10(9):632-638.
[60] KOISTINEN V, HÄRKÖNEN K, KÄRNÄ R, et al.EMT induced by EGF and wounding activates hyaluronan synthesis machinery and EV shedding in rat primary mesothelial cells[J].Matrix Biol, 2017, 11(63):38-54.
[61] PARNIGONI A, CAON I, MORETTO P, et al.The role of the multifaceted long non-coding RNAs:a nuclear-cytosolic interplay to regulate hyaluronan metabolism[J].Matrix Biol Plus, 2021, 11:1-14.
[62] GUIN S, RU Y, AGARWAL N, et al.Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis[J].Clin Cancer Res, 2016, 22(5):1274-1283.
[63] WU C T, LIN W Y, CHEN W C, et al.Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling[J].Ann Surg Oncol, 2018, 25(12):3518-3526.
[64] JORDAN A R, LOKESHWAR S D, LOPEZ L E, et al.Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer[J].Oncotarget, 2017, 8(15):24262-24274.
[65] LIANG Z, ZHANG Q, WANG C, et al.Hyaluronic acid/Hyaluronidase as biomarkers for bladder cancer:a diagnostic meta-analysis[J].Neoplasma, 2017, 64(6):901-908. |
